Drug intelligence / Profile preview

Geltim LP

Development stage
Phase 4
Lead developer
Théa Pharmaceuticals
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Geltim LP is a preservative-free ophthalmic gel formulation of timolol maleate (0.1%), a non-selective beta-adrenergic receptor antagonist. Developed by Laboratoires Théa, it is specifically indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The formulation is designed for once-daily administration (prolonged release) and is free of preservatives such as benzalkonium chloride, which improves tolerability for patients with sensitive eyes or ocular surface disease. Timolol works by blocking beta-adrenergic receptors on the ciliary epithelium, which reduces the secretion of aqueous humor without significantly affecting pupil size or accommodation.

Brand names
Geltim LPGeltim
Other names
unpreserved timolol maleate geltimolol maleate 0.1% gel
02

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on Geltim LP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Geltim LP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call